The Experts below are selected from a list of 24 Experts worldwide ranked by ideXlab platform
Bryan Kestenbaum - One of the best experts on this subject based on the ideXlab platform.
-
heroin use is associated with aa type Kidney Amyloidosis in the pacific northwest
Clinical Journal of The American Society of Nephrology, 2018Co-Authors: Arjun Sharma, Priyanka Govindan, Mirna Toukatly, Jack Healy, Connor Henry, Steve Senter, Behzad Najafian, Bryan KestenbaumAbstract:Background and objectives AA-type Kidney Amyloidosis is classically associated with chronic autoimmune or inflammatory disorders. However, some urban centers have reported a high prevalence of injection drug use among patients with Kidney AA Amyloidosis. Previous reports lack control groups to quantify associations and most predate the opioid epidemic in the United States. Design, setting, participants, & measurements We conducted a case–control study of 38 patients with biopsy-confirmed Kidney AA Amyloidosis and 72 matched control individuals without this condition from two large hospital systems in Seattle, Washington. We ascertained the pattern and duration of heroin use by medical chart review and determined associations using logistic regression. Results Among case patients, 95% had a prior history of heroin use, 87% had skin abscesses, and 76% and 27% had evidence of muscling and skin popping, respectively. After adjustment for age, race, sex, site, and year of biopsy, any heroin use (past or current) was associated with an estimated 170-times higher risk of Kidney AA Amyloidosis compared with no heroin use (95% confidence interval, 28 to 1018 times higher; P Conclusions Injection heroin use is strongly associated with Kidney AA Amyloidosis in the Pacific Northwest. Unique aspects of heroin use, in particular geographic regions or frequent associated soft-tissue infections, may be an important cause of this progressive Kidney disease.
Sophie Georgin-lavialle - One of the best experts on this subject based on the ideXlab platform.
-
AA Amyloidosis revealing mevalonate kinase deficiency: A report of 20 cases including two new French cases and a comprehensive review of literature.
Seminars in arthritis and rheumatism, 2020Co-Authors: François Rodrigues, Laurence Cuisset, Gilles Grateau, Jean-baptiste Philit, Irina Giurgea, Dany Anglicheau, Jean-jacques Roux, Nadia Hoyeau, Sophie Georgin-lavialleAbstract:Abstract Introduction Mevalonate kinase deficiency (MKD) is a rare autosomal recessive autoinflammatory disease that can lead to an inflammatory A Amyloidosis (AA). Methods To study the occurrence of AA in MKD patients we performed a systemic review of the literature and described two novel patients. Results Amyloidosis occurred in 20 MKD patients, renal impairment being always the revealing symptom of AA. Although an accurate prevalence estimation is not possible since exact MKD prevalence is unknown, AA seems rare in MKD (about 6% if we estimate MKD prevalence at 300 patients worldwide). MVK gene study, available in 18 out of the 20 patients, confirmed two pathogenic mutations in all tested individuals. The most frequent genotype was V377I/I268T (n = 9/18). Retrospective search of clinical signs of MKD established, in all patients carrying MVK pathogenic mutations, a disease onset within the first four years of life. Nephrotic syndrome (n = 15), end-stage renal failure (n = 5) or both (n = 8) pointed out Kidney Amyloidosis. The youngest patient with renal Amyloidosis was a European four-year-old girl previously misdiagnosed with PFAPA syndrome. Five patients died of AA Amyloidosis despite the use of a biotherapy for two of them; Kidney transplant was performed in nine individuals. Colchicine was not effective in any patient. Anti-interleukin-1 anakinra (n = 8), anti TNF etanercept (n = 7) and anti-interleukin 6 tocilizumab (n = 5) treatments were partially effective. Conclusion Inflammatory A Amyloidosis, a rare complication of MKD, can cause death or necessitate Kidney transplantation. Early diagnosis and cytokine blocking biotherapy using anti-IL1, anti-TNF or anti-IL6 agents are required to prevent terminal renal failure.
Arjun Sharma - One of the best experts on this subject based on the ideXlab platform.
-
heroin use is associated with aa type Kidney Amyloidosis in the pacific northwest
Clinical Journal of The American Society of Nephrology, 2018Co-Authors: Arjun Sharma, Priyanka Govindan, Mirna Toukatly, Jack Healy, Connor Henry, Steve Senter, Behzad Najafian, Bryan KestenbaumAbstract:Background and objectives AA-type Kidney Amyloidosis is classically associated with chronic autoimmune or inflammatory disorders. However, some urban centers have reported a high prevalence of injection drug use among patients with Kidney AA Amyloidosis. Previous reports lack control groups to quantify associations and most predate the opioid epidemic in the United States. Design, setting, participants, & measurements We conducted a case–control study of 38 patients with biopsy-confirmed Kidney AA Amyloidosis and 72 matched control individuals without this condition from two large hospital systems in Seattle, Washington. We ascertained the pattern and duration of heroin use by medical chart review and determined associations using logistic regression. Results Among case patients, 95% had a prior history of heroin use, 87% had skin abscesses, and 76% and 27% had evidence of muscling and skin popping, respectively. After adjustment for age, race, sex, site, and year of biopsy, any heroin use (past or current) was associated with an estimated 170-times higher risk of Kidney AA Amyloidosis compared with no heroin use (95% confidence interval, 28 to 1018 times higher; P Conclusions Injection heroin use is strongly associated with Kidney AA Amyloidosis in the Pacific Northwest. Unique aspects of heroin use, in particular geographic regions or frequent associated soft-tissue infections, may be an important cause of this progressive Kidney disease.
Samborski Włodzimierz - One of the best experts on this subject based on the ideXlab platform.
-
Renal Amyloidosis secondary to rheumatoid arthritis effectively treated with tocilizumab
'VM Media SP. zo.o VM Group SK', 2018Co-Authors: Sikorska Dorota, Samborski WłodzimierzAbstract:Kidney Amyloidosis is one of the most serious potential complication of chronic inflammatory disorders, including rheumatoid arthritis. Interleukin-6 blockade is frequently effective in rheumatic disease, however, there are only few published data on its use in AA Amyloidosis. Here, we report a case of patient with rheumatoid arthritis complicated by nephrotic syndrome due to secondary type A Amyloidosis successfully treated with tocilizumab. Forum Reumatol. 2018, tom 4, nr 3: 184–18
François Rodrigues - One of the best experts on this subject based on the ideXlab platform.
-
AA Amyloidosis revealing mevalonate kinase deficiency: A report of 20 cases including two new French cases and a comprehensive review of literature.
Seminars in arthritis and rheumatism, 2020Co-Authors: François Rodrigues, Laurence Cuisset, Gilles Grateau, Jean-baptiste Philit, Irina Giurgea, Dany Anglicheau, Jean-jacques Roux, Nadia Hoyeau, Sophie Georgin-lavialleAbstract:Abstract Introduction Mevalonate kinase deficiency (MKD) is a rare autosomal recessive autoinflammatory disease that can lead to an inflammatory A Amyloidosis (AA). Methods To study the occurrence of AA in MKD patients we performed a systemic review of the literature and described two novel patients. Results Amyloidosis occurred in 20 MKD patients, renal impairment being always the revealing symptom of AA. Although an accurate prevalence estimation is not possible since exact MKD prevalence is unknown, AA seems rare in MKD (about 6% if we estimate MKD prevalence at 300 patients worldwide). MVK gene study, available in 18 out of the 20 patients, confirmed two pathogenic mutations in all tested individuals. The most frequent genotype was V377I/I268T (n = 9/18). Retrospective search of clinical signs of MKD established, in all patients carrying MVK pathogenic mutations, a disease onset within the first four years of life. Nephrotic syndrome (n = 15), end-stage renal failure (n = 5) or both (n = 8) pointed out Kidney Amyloidosis. The youngest patient with renal Amyloidosis was a European four-year-old girl previously misdiagnosed with PFAPA syndrome. Five patients died of AA Amyloidosis despite the use of a biotherapy for two of them; Kidney transplant was performed in nine individuals. Colchicine was not effective in any patient. Anti-interleukin-1 anakinra (n = 8), anti TNF etanercept (n = 7) and anti-interleukin 6 tocilizumab (n = 5) treatments were partially effective. Conclusion Inflammatory A Amyloidosis, a rare complication of MKD, can cause death or necessitate Kidney transplantation. Early diagnosis and cytokine blocking biotherapy using anti-IL1, anti-TNF or anti-IL6 agents are required to prevent terminal renal failure.
